Kronos Bio, INC

Kronos Bio, Inc. has successfully completed its merger with Concentra Biosciences, LLC, becoming a wholly-owned subsidiary and leading to the delisting of its common stock from Nasdaq.

Kronos Bio, Inc. has announced the early termination of its Cambridge office and laboratory lease, effective June 30, 2025, leading to an estimated $18.2 million in aggregate cost savings, while also referencing an ongoing tender offer and merger.

Kronos Bio has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire Kronos Bio for $0.57 in cash per share plus a contingent value right (CVR).

Kronos Bio, Inc. terminated its office lease agreement for its corporate headquarters in San Mateo, California, effective April 30, 2025, resulting in a net payment of $1.4 million and an estimated savings of $0.2 million.

Kronos Bio reports its fourth quarter and full year 2024 financial results, including a net loss of $25.8 million for the quarter and $86.1 million for the year, while also evaluating strategic alternatives.

Kronos Bio has terminated its collaboration agreement with Genentech, transferring related assets and intellectual property in exchange for a one-time payment.

Kronos Bio reports Q1 2025 financial results, highlighted by a net loss of $8.364 million, and announces a definitive merger agreement with Concentra Biosciences.

Kronos Bio discontinues its lead clinical program, istisociclib, and initiates a strategic review process to maximize stockholder value.

Kronos Bio's second quarter 2024 results show a net loss of $16.2 million, reflecting ongoing restructuring efforts and continued investment in research and development.

Kronos Bio's first quarter 2024 results reflect a net loss of $30 million, impacted by restructuring costs and asset impairments, despite a revenue increase from a collaboration agreement.

Kronos Bio files an amendment to its 2024 Form 10-K to include Part III information regarding directors, executive officers, compensation, and related matters.

Kronos Bio discontinues istisociclib development, initiates strategic review, and reports a net loss of $86.1 million for 2024.

Kronos Bio has entered into separation agreements with two executive officers, outlining severance benefits including payments, healthcare continuation, and equity acceleration.

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Katherine V. Stultz disposed of over 100,000 stock options as part of the company's acquisition by Concentra Biosciences, with options having an exercise price above the cash offer cancelled for no cash consideration.

Arie Belldegrun, a director of Kronos Bio, Inc., reported the disposition of over 3.4 million common shares and the cancellation of 122,600 stock options as a result of the company's acquisition by Concentra Biosciences.

Norbert W. Bischofberger, a Director and 10% Owner of Kronos Bio, Inc., has reported the disposition of all his common stock and employee stock options in the company following its acquisition by Concentra Biosciences, LLC.

Kronos Bio, Inc. Director Elena Ridloff has filed a Form 4 detailing the disposition of common stock and the cancellation of stock options as a direct result of the company's acquisition by Concentra Biosciences, LLC.

David M. Tanen, a Director of Kronos Bio, Inc., has reported the complete disposition of his direct and indirect common stock and stock option holdings in connection with the company's acquisition by Concentra Biosciences.

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Roshawn A. Blunt's stock options were cancelled without consideration as part of the company's acquisition by Concentra Biosciences, LLC.

Kronos Bio announces the appointment of Deborah Knobelman as Chief Financial Officer and Chief Operations Officer, effective June 3, 2024, replacing Sandra Gardiner.

Kronos Bio, Inc. has filed a definitive proxy statement with the SEC.

Kronos Bio will hold its 2024 Annual Meeting of Stockholders virtually on June 25, 2024, to vote on the election of directors, executive compensation, and the ratification of its independent accounting firm.

Kronos Bio, Inc. has been acquired by Concentra Biosciences, LLC, leading to the complete divestment of common stock by Norbert Bischofberger, Ph.D. and related trusts.